盤中異動 | 康希諾生物-B盤中下跌8%,報於142.3港元
2022年3月25日14時51分,康希諾生物-B(HK06185)盤中下跌8%,報於142.3港元,成交額達1.44億港元,換手率達到0.7%。
3月14日訊,APP獲悉,根據聯交所最新權益披露資料顯示,2022年3月7日,康希諾生物-B(06185.HK)獲JPMorganChase&Co.以每股均價123.1682港元增持好倉16.5萬股,涉資約2031.9萬港元。增持後,JPMorganChase&Co.最新持好倉數目爲1196.958萬股,持好倉比例由8.89%上升至9.02%。
2月28日,瑞銀:維持康希諾生物-B(06185)“買入”評級,目標價降40.2%至216港元。2月21日,國金證券:維持康希諾生物-B(06185)“買入”評級,新冠疫苗獲批用於序貫加強免疫接種。2月15日,安信國際:建議關注創新藥企的長期成長價值。
最新的財務數據顯示,公司於2021年4季度,營業收入43.0億人民幣,淨利潤19.14億人民幣;營業收入同比增加23086.11%,毛利潤同比增加42222.04%,淨利潤同比增加582.65%。
盈立趨勢長盈模型最近一次交易信號,2022年3月21日出現關注信號,觸發價格爲142.8港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.